ANTONUZZO, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.040
AS - Asia 8.375
EU - Europa 7.557
SA - Sud America 953
AF - Africa 153
OC - Oceania 127
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.208
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.859
RU - Federazione Russa 3.195
CN - Cina 2.543
SG - Singapore 2.472
IT - Italia 1.483
HK - Hong Kong 1.133
KR - Corea 895
BR - Brasile 759
IE - Irlanda 573
PL - Polonia 440
FI - Finlandia 420
VN - Vietnam 309
IN - India 290
SE - Svezia 286
DE - Germania 285
ID - Indonesia 184
GB - Regno Unito 168
FR - Francia 152
JO - Giordania 132
AU - Australia 126
NL - Olanda 126
AT - Austria 98
CA - Canada 96
JP - Giappone 93
CH - Svizzera 82
AR - Argentina 76
ES - Italia 59
MX - Messico 57
TR - Turchia 52
EC - Ecuador 42
BD - Bangladesh 41
UA - Ucraina 37
TW - Taiwan 36
ZA - Sudafrica 33
IL - Israele 32
BE - Belgio 28
MA - Marocco 27
IQ - Iraq 25
PK - Pakistan 25
BJ - Benin 24
DK - Danimarca 23
AE - Emirati Arabi Uniti 21
CI - Costa d'Avorio 21
HU - Ungheria 21
CO - Colombia 18
CZ - Repubblica Ceca 17
LU - Lussemburgo 16
CL - Cile 14
IR - Iran 14
VE - Venezuela 13
UY - Uruguay 11
UZ - Uzbekistan 11
EG - Egitto 10
GR - Grecia 10
LT - Lituania 10
PY - Paraguay 10
SA - Arabia Saudita 10
MY - Malesia 9
KE - Kenya 8
PE - Perù 8
TH - Thailandia 8
DZ - Algeria 7
PH - Filippine 7
TN - Tunisia 7
NO - Norvegia 6
PA - Panama 6
BW - Botswana 5
DO - Repubblica Dominicana 5
NP - Nepal 5
TT - Trinidad e Tobago 5
AL - Albania 4
BB - Barbados 4
KW - Kuwait 4
LV - Lettonia 4
AZ - Azerbaigian 3
BY - Bielorussia 3
GA - Gabon 3
HR - Croazia 3
LK - Sri Lanka 3
OM - Oman 3
RO - Romania 3
SN - Senegal 3
AM - Armenia 2
BH - Bahrain 2
CR - Costa Rica 2
EE - Estonia 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
PS - Palestinian Territory 2
SS - ???statistics.table.value.countryCode.SS??? 2
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
DJ - Gibuti 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GN - Guinea 1
Totale 26.196
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.939
Singapore 1.865
Ashburn 1.199
Hefei 1.087
Hong Kong 985
Seoul 876
Dublin 567
Warsaw 430
San Jose 419
Helsinki 292
Fairfield 279
Florence 273
Chandler 270
Beijing 269
Los Angeles 197
Buffalo 180
Moscow 180
Jakarta 154
Seattle 147
Kent 132
Milan 132
Munich 130
Dallas 122
Melbourne 122
The Dalles 118
Woodbridge 110
Wilmington 107
Rome 105
Cambridge 103
Ho Chi Minh City 101
Lawrence 101
Houston 96
Shanghai 96
New York 93
Altamura 92
Mumbai 90
São Paulo 89
Vienna 88
Boston 86
Paris 83
Boardman 80
Bengaluru 76
Princeton 61
Hanoi 60
Bern 59
Lappeenranta 59
Turku 58
Ann Arbor 57
Tokyo 55
London 54
Chicago 49
Pune 49
West Jordan 48
San Diego 33
Brescia 30
Guangzhou 26
Yubileyny 25
Cotonou 24
Frankfurt am Main 24
Madrid 24
Brooklyn 23
Redondo Beach 22
Vancouver 22
Abidjan 21
Taipei 21
Amsterdam 20
Groningen 20
Johannesburg 20
Toronto 20
San Francisco 19
Brasília 18
Brussels 18
Copenhagen 18
Dong Ket 18
Montreal 18
Naples 18
Rio de Janeiro 17
Turin 17
Bremen 16
Jacksonville 16
Remich 16
Tel Aviv 16
Tianjin 16
Arezzo 15
Belo Horizonte 15
Medford 15
Mexico City 15
Nuremberg 15
Porto Alegre 15
Stockholm 15
Bologna 14
Chennai 14
Council Bluffs 14
Istanbul 14
Perugia 14
Sheffield 14
Columbus 13
Haiphong 13
Pisa 13
Atlanta 12
Totale 16.425
Salva come PNG Salva come JPEG
Nome #
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer 1.036
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy 314
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer 257
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC 249
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 248
Identification of predictive biomarkers of clinical benefits to immunotherapy in pre-treated advanced non-small cell lung cancer: a retrospective observational study 218
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 214
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 213
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 212
SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY PERCUTANEOUS ETHANOL INJECTION: A 10-YEAR EXPERIENCE. 211
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients 211
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 210
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 199
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature 198
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 190
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 189
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 186
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 182
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 182
Current status and future perspectives in HER2 positive advanced gastric cancer 179
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 177
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy 177
Single-stage operation using hypothermic circulatory arrest to remove uterine intravenous leiomyomatosis extended to the vena cava and right atrium 176
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 176
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 175
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 175
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 172
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 170
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 169
Circulating tumour cells in colorectal cancer 169
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 168
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 168
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 166
Analysis and optimization of clinical pathway of a cancer patient in a University Hospital 165
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes 163
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 162
Somatostatin analogs in pregnant patients with neuroendocrine tumor 162
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs 161
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors 160
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 160
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 160
Results of the observational prospective RealFLOT study 159
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 158
ROS1 rearrangements are uncommon in biliary tract cancers 157
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 157
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature 157
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis 157
Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer 156
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression 156
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation 155
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 155
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 155
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 155
Systemic Sclerosis Association with Malignancy 154
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 154
Soft tissue sarcoma: An insight on biomarkers at molecular, metabolic and cellular level 154
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival 153
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 152
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib 152
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 151
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles 151
Occurrence of Dysgeusia in Patients Being Treated for Cancer 151
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 150
Real-world study of everolimus in advanced progressive neuroendocrine tumors 150
Time-resolved autofluorescence imaging of freshly excised liver biopsies using an optical fiber probe 149
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 149
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 148
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 147
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 147
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors 146
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 144
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 143
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 143
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25) 143
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 143
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 143
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 143
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program 142
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 139
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 139
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial 138
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma 138
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 138
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 136
Delineation of gastrointestinal tumors biopsies using a fluorescence lifetime imaging optical fiber probe 136
KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients 136
Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature 136
Skin metastasis from typical carcinoid tumor of the lung. 136
Regorafenib also can cause osteonecrosis of the jaw 136
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report 136
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 135
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 134
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 134
Successful Use of Cemiplimab in a Very Elderly Patient With Cutaneous Squamous Cell Carcinoma 133
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 133
Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19) 133
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 132
Deciphering the Renal tumOr microenvironment to PersonaLize immunE-targeted Treatment (DROPLET): transcriptomic profiling of primary and secondary lesions identified a potential crosstalk between MARCO+ macrophages and deregulated cancer-cell proliferation in mediating progression and therapy response of advanced renal cell carcinoта. 131
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 131
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy 130
Totale 17.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.019
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021338 0 0 0 0 0 0 37 64 60 87 55 35
2021/2022461 9 33 45 13 18 12 13 65 34 22 69 128
2022/20232.132 103 285 67 153 109 413 301 272 237 31 78 83
2023/20241.905 39 98 168 129 117 270 113 393 68 197 155 158
2024/202510.821 311 913 580 1.591 2.563 1.508 381 613 610 383 568 800
2025/20269.898 1.626 2.006 2.018 1.400 1.548 547 753 0 0 0 0 0
Totale 26.602